Author:
Duarsa Gede W.K.,Oka Anak A. G.,Maliawan Sri,Soebadi Doddy M.,Astawa Putu,Bakta Made,Sukrama Dewa M.,Manuaba Ida B. P.,Astawa Nyoman M.
Abstract
Background:
Lower Urinary Tract Symptoms (LUTS) after Transurethral Resection of the Prostate (TURP) occur in one-third of Benign Prostatic Hyperplasia (BPH) patients, may be caused by persistent prostatic inflammation and fibrosis.
Objective:
This study aims to evaluate the role of inflammation and fibrosis in pathological mechanism of LUTS among patients with BPH who underwent TURP by assessing their PSA, TNF-α, and TGF-β level.
Design, Setting, and Participant:
Data in this study were analyzed with the 2-way hypothesis. The study used odds ratio to define the risk factors of LUTS after TURP. The samples of the study are BPH patients after TURP aged 50-80 years old.
Interventions:
No intervention(s).
Outcome Measurements and Statistical Analysis:
The data analyzed using SPSS version 21.0 for Windows.
Results and Limitations:
There were 34 cases of LUTS and 42 controls without LUTS. We found that there were an increased levels of TNF-α (> 46.95 pg/ml) (OR 55.6, 95% Confidence Interval [CI] 11.1-278.4, p=0.00) and TGF-β (> 207.63 pg/ml) (OR 16.7, 95%CI 5.3-52.8, p=0.00). The result of multiple linear logistic regression analysis obtained equation Y= 0.033 x TNF-α + 0.031 x TGF-β. Population Attributable Risk (PAR) % TNF-α is 60%, PAR % TGF-β is 53%.
Conclusion:
Combination of elevated levels of TNF-α (>46.95 pg/ml) and TGF-β (>207.63) in prostate tissue is the risk factors for the occurrence of LUTS after TURP.
Patient Summary:
In this study, we enrolled 76 patients who were diagnosed with BPH and urinary retention. After TURP, there were 34 cases of LUTS and 42 controls without LUTS. We found that the levels of TNF-α and TGF-β between cases and controls were significantly different. We conclude that the combination of elevated levels of TNF-α and TGF-β in prostate tissue is the risk factors for the occurrence of LUTS after TURP.
Publisher
Bentham Science Publishers Ltd.
Reference33 articles.
1. Vary M.
American urological association guideline Management of Benign prostatic Hyperplasia (BPH)
2010;
2-18.
2. Oelke M, Bachmann A, Descazeaud A, et al.
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
Eur Urol
2013;
64
(1)
: 118-40.
3. Chughtai B, Lee R, Te A, Kaplan S.
Role of inflammation in benign prostatic hyperplasia.
Rev Urol
2011;
13
(3)
: 147-50.
https:// www. ncbi .nlm.nih.gov /pmc/articles/ pmc3221555/
4. Mochtar CA, Umbas R, Soebadi DM.
Clinical guideline benign prostate hyperplasia management (Benign Prostatic Hyperplasia/BPH) 2nd. Ed.
2015;
1-27.
5. Duarsa GWK, Lesmana R, Mahadewa TGB.
High serum prostate specific antigen serum as a risk factor for moderate-severe prostate inflammation in patient with benign prostate hyperplasia.
Bali Med J
2016;
4
(3)
: 148-51.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献